Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Ranibizumab in neovascular age-related macular degeneration Kenneth TE; Kertes PJClin Interv Aging 2006[]; 1 (4): 451-66Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration.|Age Factors[MESH]|Aging/*physiology[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/pharmacology/*therapeutic use[MESH]|Bevacizumab[MESH]|Humans[MESH]|Macular Degeneration/*drug therapy[MESH]|Neovascularization, Pathologic/drug therapy[MESH]|Ranibizumab[MESH]|Retinal Neovascularization/drug therapy[MESH]|Visual Acuity/drug effects[MESH] |